Skip to main content
Year archive

Theranexus — 2020 filings

All 37 regulatory filings released by Theranexus (ALTHX) in 2020, sourced directly from the official regulator.

37 Filings
2020 Period
2020 filings (37)
Filing Released Lang
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021
Report Publication Announcement
2020-12-28 English
THERANEXUS PUBLIE SON AGENDA FINANCIER 2021
Report Publication Announcement
2020-12-28 French
THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP ANNONCENT LA CRÉATION ET LE FINANCEMENT D'UN NOUVEAU LABORATOIRE COMMUN PUBLIC/PRIVÉ ' NEURO-IMAGING FOR DRUG DISCOVERY ' (NI2D
Regulatory Filings
2020-12-18 French
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP ANNOUNCE THE CREATION AND FUNDING OF NEW JOINT PUBLIC/PRIVATE LABORATORY 'NEUROIMAGING FOR DRUG DISCOVERY' (NI2D)
Regulatory Filings
2020-12-18 English
THE FOOD AND DRUG ADMINISTRATION (FDA) ISSUES A FAVORABLE OPINION ON THE PRECLINICAL DEVELOPMENT PLAN SUBMITTED BY THERANEXUS AND BBDF
Regulatory Filings
2020-11-19 English
LA FOOD AND DRUG ADMINISTRATION (FDA) REND UN AVIS FAVORABLE AU PLAN DE DEVELOPPEMENT PRÉCLINIQUE DÉPOSÉ PAR THERANEXUS ET LA FONDATION BBDF
Regulatory Filings
2020-11-19 French
PRESENTATION OF THE RESULTS OF THE PHASE IB CLINICAL STUDY OF THN201 FOR ALZHEIMER'S DISEASE AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
Investor Presentation
2020-11-04 English
PRÉSENTATION DES RÉSULTATS DE L'ÉTUDE CLINIQUE DE PHASE 1b AVEC THN201 DANS LA MALADIE D'ALZHEIMER LORS DU CONGRES ' CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) '
Investor Presentation
2020-11-04 French
THERANEXUS AND BBDF OBTAIN EUROPEAN 'ORPHAN MEDICINAL PRODUCT' DESIGNATION FOR BBDF-101 IN BATTEN DISEASE
Regulatory Filings
2020-10-21 English
THERANEXUS ET LA FONDATION BBDF OBTIENNENT LE STATUT DE ' MÉDICAMENT ORPHELIN' EN EUROPE POUR BBDF-101 DANS LA MALADIE DE BATTEN
Regulatory Filings
2020-10-21 French
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2020
Earnings Release 9M 2020
2020-10-15 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2020
Earnings Release 9M 2020
2020-10-15 French
THERANEXUS ANNOUNCES ITS FIRST HALF 2020 RESULTS
Earnings Release H1 2020
2020-09-29 English
RESULTATS DU PREMIER SEMESTRE 2020
Earnings Release H1 2020
2020-09-29 French
THERANEXUS PRESENTS ITS LATEST SCIENTIFIC NEWS
Regulatory Filings
2020-09-09 English
THERANEXUS FAIT LE POINT SUR SON ACTUALITÉ SCIENTIFIQUE
Regulatory Filings
2020-09-09 French
INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change
2020-09-07 French
DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements
2020-09-07 English
THERANEXUS ET LA FONDATION BBDF OBTIENNENT LE STATUT DE ' MÉDICAMENT ORPHELIN (ODD) ' ET LA DÉSIGNATION DE ' MALADIE RARE PEDIATRIQUE (RPDD)' PAR LA FOOD AND DRUG ADMINISTRATION (FDA) POUR BBDF-101 DA
Regulatory Filings
2020-08-11 French
THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) FOR BBDF-101 FOR BATTEN DISEASE
Regulatory Filings
2020-08-11 English
DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements
2020-08-06 English
INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change
2020-08-06 French
THERANEXUS TO PRESENT THE RESULTS OF THN102 FOR PARKINSON'S DISEASE AT THE 2020 INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS
Regulatory Filings
2020-07-30 English
THERANEXUS PRÉSENTERA LES RÉSULTATS DE THN102 DANS LA MALADIE DE PARKINSON A L'INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS (MDS) 2020
Regulatory Filings
2020-07-30 French
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE - 1er SEMESTRE 2020
Transaction in Own Shares
2020-07-20 French
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 AND IMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY
Capital/Financing Update
2020-07-09 English
THERANEXUS ANNONCE SA POSITION DE TRÉSORERIE AU 30 JUIN 2020 ET LA MISE EN PLACE D'UNE LIGNE DE FINANCEMENT EN FONDS PROPRES
Capital/Financing Update
2020-07-09 French
THERANEXUS OBTIENT UN FINANCEMENT NON DILUTIF DE 3,4 M EUR SOUS FORME DE PRÊT GARANTI (PGE) PAR L'ÉTAT ET FAIT LE POINT SUR SES DEVELOPPEMENTS
Earnings Release H1 2020
2020-06-24 French
THERANEXUS SECURES EUR 3.4 M LOAN UNDER THE FRENCH STATE GUARANTEE SCHEME (PGE) AND PROVIDES AN UPDATE ON ITS DEVELOPMENTS
Capital/Financing Update
2020-06-24 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2020-02-04 French
DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements
2020-02-04 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2019
Earnings Release Q4 2019
2020-01-27 French
THERANEXUS REPORTS CASH POSITION AS OF DECEMBER 31, 2019
Regulatory Filings
2020-01-27 English
THERANEXUS PUBLIE SON AGENDA FINANCIER 2020
Report Publication Announcement
2020-01-20 French
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2020
Report Publication Announcement
2020-01-20 English
THERANEXUS ANNOUNCES THE CLINICAL RESULTS OF ITS PHASE IB STUDY DEMONSTRATING THE EXTENDED PHARMACOLOGICAL PROFILE OF ITS DRUG CANDIDATE THN201 COMPARED TO DONEPEZIL
Regulatory Filings
2020-01-15 English
THERANEXUS ANNONCE LES RÉSULTATS CLINIQUES DE SON ÉTUDE DE PHASE IB MONTRANT UN ÉLARGISSEMENT DU PROFIL PHARMACOLOGIQUE DE SON CANDIDAT MÉDICAMENT THN201 PAR RAPPORT AU DONÉPÉZIL
Earnings Release FY 2020
2020-01-15 French